The association between antiphospholipid antibodies and late fetal loss: A systematic review and meta‐analysis

Xu, Jinfeng; Chen, Daijuan; Duan, Xia; Li, Li; Tang, Yuxin; Peng, Bing

doi:10.1111/aogs.13665

Cited by 30 publications

(18 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antiphospholipid antibodies (aPL) are the main predictors of pregnancy complications, including miscarriage, fetal death, prematurity and preeclampsia, with lupus anticoagulant (LAC) being strongly associated with miscarriage and late fetal loss [6][7][8]. Furthermore, infants of mothers with SLE who were exposed to anti-Ro/SSA or anti-La/SSB antibodies during pregnancy have shown an increased risk for neonatal lupus syndrome, with its most serious manifestation being fetal heart block [6,9,10].…”

Section: Introductionmentioning

confidence: 99%

Maternal Systemic Lupus Erythematosus (SLE) High Risk for Preterm Delivery and Not for Long-Term Neurological Morbidity of the Offspring

Davidov

Wainstock

Miodownik

et al. 2021

JCM

View full text Add to dashboard Cite

Objective: Pregnancies of women with systemic lupus erythematosus (SLE) are associated with preterm delivery. As preterm delivery is associated with long-term neurological morbidity, we opted to evaluate the long-term neurologic outcomes of offspring born to mothers with SLE regardless of gestational age. Methods: Perinatal outcomes and long-term neurological disease of children of women with and without SLE during pregnancy were evaluated. Children of women with and without SLE were followed until 18 years of age for neurological diseases. Generalized estimating equation (GEE) models were used to assess perinatal outcomes. To compare cumulative neurological morbidity incidence a Kaplan–Meier survival curve was used, and a Cox proportional hazards model was used to control for confounders. Result: A total of 243,682 deliveries were included, of which 100 (0.041%) were of women with SLE. Using a GEE model, maternal SLE was noted as an independent risk factor for preterm delivery. The cumulative incidence of long-term neurological disease was not found to be significantly higher when using the Kaplan Meier survival curves and maternal SLE was not found to be associated with long-term neurological disease of the offspring when a Cox model was used. Conclusion: Despite the association of SLE with preterm delivery, no difference in long-term neurological disease was found among children of women with or without SLE.

show abstract

Section: Introductionmentioning

confidence: 99%

Maternal Systemic Lupus Erythematosus (SLE) High Risk for Preterm Delivery and Not for Long-Term Neurological Morbidity of the Offspring

Davidov

Wainstock

Miodownik

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…In the cases of late gestational loss, lupus anticoagulant was more closely related to RPL than any of the other antibodies [26,27]. Anticardiolipin (IgG and IgM) has been associated with early and late gestational loss [26,27]. The relationship between anti-β2GP1 and late gestational loss seems to be controversial [26,27].…”

Section: Acquired Thrombophiliasmentioning

confidence: 99%

“…Anticardiolipin (IgG and IgM) has been associated with early and late gestational loss [26,27]. The relationship between anti-β2GP1 and late gestational loss seems to be controversial [26,27]. ESHRE recommends for patients with two losses, consecutive or not, to conduct a research for lupus anticoagulant antibodies and anticardiolipin, and the research should consider anti-β2GP1.…”

Section: Acquired Thrombophiliasmentioning

confidence: 99%

Recurrent Pregnancy Loss: Investigations and Interventions

Lopes¹,

Souza-Oliveira²,

Goulart³

et al. 2020

Innovations in Assisted Reproduction Technology

View full text Add to dashboard Cite

Recurrent pregnancy loss (RPL) affects 0.8-1.4% of couples, and this prevalence increases with aging. However, etiology is commonly unknown, and most therapies are not supported by strong evidence. There are many examinations that investigate causes of RPL: hormonal status, spermatozoa morphology and DNA fragmentation, immunologic status, uterine assessment, thrombophilia, and others. Recently different types of treatment have emerged, most lacking good evidence. As for example, we may mention the use of anticoagulants, aspirin, corticosteroids, progesterone, and antioxidants and psychological support. It is argued that some procedures such as preimplantation genetic testing for aneuploidy and intracytoplasmic morphologically selected sperm injection would impact on the outcomes and help RPL management. This chapter will discuss the current evidence concerning examinations and treatments that would improve the outcomes in patients with RPL, with recommended practice.

show abstract

“…Information Sources and Search Strategy. We followed the methods of Xu et al [10]. A systematic search of the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) database was conducted up to 1 November, 2021.…”

mentioning

confidence: 99%

Antiphospholipid Antibodies Increase the Risk of Fetal Growth Restriction: A Systematic Meta-Analysis

Chen

Tian

et al. 2022

International Journal of Clinical Practice

Self Cite

View full text Add to dashboard Cite

Objective. Antiphospholipid syndrome (APS) is a chronic autoimmune disease with a high prevalence in females. Published data have identified pregnant women with APS may suffer from recurrent miscarriage, fetal death. However, the association between antiphospholipid antibody (aPL) and fetal growth restriction (FGR) remains controversial. This study aims to systematically review the literature on population-based studies investigating an association between aPL and FGR. Methods. The literature was searched on 1 November, 2021, using Ovid MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL), following the MOOSE checklist. Study inclusion criteria focused on peer-reviewed published articles that reported an association between aPL and FGR. Quality assessment was performed based on the Newcastle-Ottawa scale. The between-study heterogeneity was assessed by the Q test. Publication bias was assessed by funnel plots. Results. Twenty-two studies (with 11745 pregnant women) were included in the final analysis. Pooled odds ratio for association of aPL, anticardiolipin antibodies (ACA), anti-beta2 glycoprotein 1 antibodies (β2GP1), and FGR was 1.26 (95%CI 1.12, 1.40), 2.25 (95%CI 1.55, 2.94), and 1.31 (95% CI 1.12, 1.49), respectively. Lupus anticoagulant (LA) did not increase the chance of FGR (OR 0.82, 95%CI 0.54, 1.10). Conclusions. Our meta-analysis showed that aPL increased the risk of FGR. The risk of FGR varies with the aPL types. ACA and β2GP1 are strongly associated with FGR. There are currently insufficient data to support a significant relationship between LA and FGR.

show abstract

The association between antiphospholipid antibodies and late fetal loss: A systematic review and meta‐analysis

Cited by 30 publications

References 45 publications

Maternal Systemic Lupus Erythematosus (SLE) High Risk for Preterm Delivery and Not for Long-Term Neurological Morbidity of the Offspring

Maternal Systemic Lupus Erythematosus (SLE) High Risk for Preterm Delivery and Not for Long-Term Neurological Morbidity of the Offspring

Recurrent Pregnancy Loss: Investigations and Interventions

Antiphospholipid Antibodies Increase the Risk of Fetal Growth Restriction: A Systematic Meta-Analysis

Contact Info

Product

Resources

About